Proteomics Market Forecasts to 2028 – Global Analysis By Analysis Type (Protein Expression Proteomics, Structural Proteomics, Functional Proteomics), Component (Services, Instruments, Reagents), Technology (Protein Microarray Instruments, Spectroscopy, X-

Proteomics Market Forecasts to 2028 – Global Analysis By Analysis Type (Protein Expression Proteomics, Structural Proteomics, Functional Proteomics), Component (Services, Instruments, Reagents), Technology (Protein Microarray Instruments, Spectroscopy, X-Ray Crystallography), Service, Application, End User and Geography

According to Stratistics MRC, the Global Proteomics Market is accounted for $25.75 billion in 2022 and is expected to reach $61.14 billion by 2028 growing at a CAGR of 15.5% during the forecast period. Proteomic analysis is the systematic study of the proteome on a larger scale in order to collect information on protein abundances, variations, and alterations, as well as their interacting partners and networks, in order to comprehend cellular processes. Proteomics research is widely used in a variety of scientific fields, including the study and treatment of disease, the discovery of diagnostic biomarkers, the phenotyping of plants and animals, microbiology, drug discovery and development, toxicological testing, and antibody profiling.

According to Globocan, 19.3 new cancer cases were reported worldwide in December 2020, with 10 million cancer-related deaths reported. Similarly, CVDs are a significant cause of death worldwide. For instance, the WHO (2021) states that 41 million patients die yearly from target diseases.

Market Dynamics:

Driver:

Detection of Biomarkers

Greater insight into the workings of disease processes may be gained by identifying and examining disease-specific biomarkers in situations as various as cancer, neurological disorders, and cardiovascular diseases. This advances knowledge of drug interactions and their impact on the metabolic pathway, which aids in the development of novel medications. The promise of proteomic technologies is enormous, notably in the quest for novel clinical biomarkers for the early detection and diagnosis of cancer and other illnesses as well as the identification of novel therapeutic targets from readily available bio-specimens. Differential in-gel electrophoresis (DIGE), a relatively new method, is claimed to be an efficient proteomic method for the molecular characterization of tumour development and the detection of tumor-specific biomarkers in esophageal scans cell cancer when used in conjunction with liquid chromatography and mass spectrometry (LC/MS). Therefore, the proteomics industry has a lot of room for growth as a consequence of the discovery of novel biomarkers.

Restraint:

High Costs Associated with the Components of Proteomics

The price of proteomics goods is costly, which restricts the market's expansion since it is necessary to uphold high quality standards and adhere to regulations established by regulatory bodies. Only top-notch materials, equipment, reagents, and other items will produce reliable findings for this investigation. The high cost of the required equipment and reagents makes it difficult for underdeveloped countries to enter the area of proteomics. The cost of the reagents and instruments did not seem to have significantly decreased during the course of the study. It is thus projected that the constraint's impact will be minimal in the not-too-distant future.

Opportunity:

Prevalence of cancer, Technical advancements & collaborations

The primary driver of the market's expansion is the rising demand for personalised medications, which is being accompanied by an increase in drug discovery and biotechnology research and development. Drug development is made easier by proteomic systems, which decrease the time, money, and resources required for drug manufacturing and biological testing. The market is also being helped by opportunities in biomarker discovery and mass spectrometry-based proteomics. Additionally, the industry is supported by the widespread use of technology in comprehensive protein analysis methods. These developments make it possible to identify cancer cures and treatments as well as conduct in-depth quantitative and qualitative analyses of proteins.

Threat:

Expensive instruments

The price of the therapy rises as more time is required in the laboratory. Because the necessary equipment and chemicals are costly, this method is not widely employed in underdeveloped countries. The most used technique for proteomics is X-ray crystallography, which is used to express proteins and clone genes. Additionally, it aids in the purification and crystallisation of proteins. These operations take a long time to complete, which makes them expensive. As a result, fewer impoverished countries will embrace these procedures. This is a significant obstacle to the market's expansion and will eventually prevent it from expanding.

Covid-19 Impact

The development of the proteomics market is another indication of COVID-19's effects. Increased investigation has been made into COVID-19 diagnostics, biomarker identification, and medication discovery and development. The application of proteomics has increased. Numerous big and small businesses are continuously developing immunoassay assays that quickly detect COVID-19. Along with businesses, a large number of public and private research institutes and organisations significantly enhanced the corona virus study using the proteomics technique.

The immunoassay segment is expected to be the largest during the forecast period

The immunoassay segment is estimated to have a lucrative growth, due to the expanding use of immunoassays in proteomics due to their high sensitivity and specificity. Another important element influencing the growth rate of the sector is the expanding range of immunoassay applications, including as clinical diagnostics, drug research and development, and biomarker identification. Multiplex immunoassays, a recent technical development that allows for simultaneous measurement of numerous proteins while being more efficient and economical. Additionally, it is anticipated that during the projection period, the use of proteomics in drug development would increase along with the need for personalised medicine.

The Drug Discovery segment is expected to have the highest CAGR during the forecast period

The Drug Discovery segment is anticipated to witness the fastest CAGR growth during the forecast period. One of the most exciting advancements in the study of human genes and proteins has been the discovery of possible new medications for the treatment of illness. The discovery of proteins linked to a disease, which may later be utilised as targets for novel medications by computer algorithms, depends on genome and proteome data. To characterise the effects of drug candidates on cellular systems and model organisms throughout the preclinical phases of the drug development process, several genetic and biochemical experiments are required. Nearly all major pharmaceutical companies collaborate with university or biotech organisations focused on proteomics, or they have established their own proteomics section. Identification of effectiveness and toxicity are two examples of the general uses of proteomics in the pharmaceutical sector.

Region with highest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to an increase in the contracting of proteomics-based projects, public and private funding for the development of technologies for proteomics studies, favourable government regulations, rising prevalence of target diseases with an ageing population, and rising proteomics adoption. The Asia-Pacific region's proteomics market is expanding as a result of an increasing number of government programmes in support of proteomics research, a rising patient population with a variety of disorders, and rising healthcare costs.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to expanding patient population with chronic illnesses and the increased desire for personalised medication. The development of the proteomics market in North America is also being aided by the region's developed healthcare infrastructure and quick uptake of cutting-edge medical technology. The pace of regional market expansion is being supporting by the increasing use of cutting-edge proteomics technologies in academic and research organisations in the North American area.

Key players in the market

Some of the key players profiled in the Proteomics Market include Luminex Corporation, Caprion Proteomics Inc., Bio-Rad Laboratories, Inc. , Thermo Fisher Scientific Inc., Bruker Corporation, Danaher Corp., Illumina, Inc., Abbott Laboratories, Biognosys AG, Merck KGaA, Siemens AG, Promega Corporation, Becton Dickinson and Company, Caprion Biosciences, Waters Corporation and PerkinElmer, Inc.

Key Developments:

In March 2022, Biognosys introduced an expanded suite of proteomics platforms, namely The TrueDiscovery, TrueTarget, and TrueSignature that provides biological insights across the entire R&D pipeline from early-stage discovery to clinical settings for pharmaceutical and diagnostics customers.

In December 2020, Thermo Fisher Scientific purchased Phitonex Inc. The addition of Phitonex's products will allow Thermo Fisher to provide expanded flow cytometry and imaging multiplexing features to meet evolving customer requirements in protein and cell analysis research.

Analysis Types Covered:
• Protein Expression Proteomics
• Structural Proteomics
• Functional Proteomics
• Other Analysis Types

Components Covered:
• Instruments
• Reagents
• Consumables
• Other Components

Technologies Covered:
• Protein Microarray Instruments
• Spectroscopy
• X-Ray Crystallography
• Other Technologies

Services Covered:
• Data Analysis and Services
• Laboratory Service
• Quantitation Services
• Analytical Laboratory Services
• Bioinformatics Software & Services
• Core Proteomics Services
• Other Services

Applications Covered:
• Proteome Mining
• Protein Expression Profiling
• Post Translational Modifications
• Other Applications

End Users Covered:
• Pharmaceutical Companies
• Clinical Laboratories
• Hospitals
• Disease Diagnosis
• Drug Discovery
• Academic Research Laboratories
• Other End Users

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements Show more